Introduction
Manipulating the cholinergic system has been shown to affect mood (Rowntree et al., 1950; Janowsky et al., 1974; Furey and Drevets, 2006) , suggesting depression and mania could result from changes in cholinergic neurotransmission (Janowsky et al., 1974) . The finding that there was an altered risk for mood disorders associated with variance in the sequence of the muscarinic M2 receptor (CHRM2) gene (Comings et al., 2002; Wang et al., 2004; Luo et al., 2005) , one of 5 CHRMs in the human CNS (Wess, 2003) , focused attention on the role of that receptor in the aetiology of mood disorders. More recently, a positron emission tomography study reported lower levels of CHRM2 (measured as the binding of 3-(3-(3-fluoroproply) thio)-1,2,5-thiadiazol-4-yl] -1,2,5,6-tetrahydro-1-methylpyridine labelled with F-18, a positron emitting radionuclide, ([ 18 F]FP-TZTP)) in Brodmann's area [BA] 24 in bipolar disorders (BPD) (Cannon et al., 2006) . Interestingly, the lower levels of [ 18 F]FP-TZTP binding in BPD was most apparent in subjects who were homozygous T genotype at rs324650 (Cannon et al., 2011) , an intronic CHRM2 single nucleotide polymorphism, that had previously been associated with an altered risk for mood disorders (Wang et al., 2004; Luo et al., 2005) .
We have reported lower levels of N- [[2, H]-methyl]-1-piperidinyl]ethyl]-5,6-dihydro-6-oxo-11H-pyrido [2,3-b] [1,4]benzodiazepine-11-carboxamide ([ 3 H]AF-DX 384) binding to BA 46 from subjects with BPD and major depressive disorder (MDD) (Gibbons et al., 2009) . This is relevant, because studies using human cloned receptors show [ 3 H]AF-DX 384 binds selectively to CHRM2 and CHRM4 (Miller et al., 1991) . Hence, our data seem to partly agree with the neuroimaging study showing lower cortical CHRM2 in BPD. Our data differ from that of another study that reported [ 3 H] AF-DX 384 binding was not altered in BA 24 from people with BPD (Zavitsanou et al., 2005) ; these apparently contradictory data could be explained by regionally selective changes in cortical [ 3 H]AF-DX 384 in mood disorders. To challenge this hypothesis, we decided to measure levels of [ 3 H]AF-DX 384 binding in BA 24, as well as BA 46, using a larger cohort of subjects with MDD, BPD, and age-/sexmatched controls than was previously available. We also determined levels of CHRM2 protein and oxotremorine-M-stimulated GTPγS binding, a surrogate measure of CHRM2 / 4 signalling in postmortem tissue , in the same cortical samples. Finally, we determined if changes in [ 3 H]AF-DX 384 binding could be part of the mechanism of action of drugs used to treat mood disorders by measuring the binding of that radioligand in rat cortex after treatment with mood stabilisers (lithium and valproate) or antidepressant drugs (imipramine and fluoxetine).
Methods and Materials

Human CNS
Human tissue was sourced through the Victorian Brain Bank Network at the Florey Institute of Neuroscience and Mental Health. The tissue was collected at the Victorian Institute of Forensic Medicine after approval from that Institution's Ethics Committee.
BA 24 (defined as the ventral anterior cingulate gyrus around the genu of the corpus callosum) and BA 46 (defined as the lateral surface of the frontal lobe, including approximately the middle one-third of the middle frontal gyrus and the most rostral portion of the inferior frontal gyrus) were taken from the left hemisphere of 15 subjects with MDD, 14 subjects with BPD, and 19 subjects with no history of psychiatric illness (controls) ( Table 1; supplementary Table 1 ). Psychiatric diagnoses were made by consensus according to DSMIV criteria (American Psychiatric, 1994) using the Diagnostic Instrument for Brain Studies (Hill et al., 1996; Roberts et al., 1998) . The designation of nonpsychiatric controls could be reached only where no indication of any psychiatric history was found after an extensive case history review and interviews with relatives. As part of the case history review, duration of illness (DI) was calculated as the time from first contact with a clinical service to death. Postmortem interval (PMI) was calculated as the time between death and autopsy or, where death was not witnessed but the subject was seen alive within 5 hours of being found dead, the midpoint between the subject being found and being last seen alive. Importantly, all cadavers were refrigerated within 6 hours and the brains frozen to -80 o C within 30 minutes of autopsy to reduce the impact of autolysis (Stan et al., 2006) . Tissue quality was assessed by measuring CNS pH (Kingsbury et al., 1995) , which is now regarded as the best measure of tissue preservation postmortem (Stan et al., 2006) .
Neuropsychopharmacological Studies
Animal experimentation was performed with the approval of the Florey Institute for Neuroscience and Mental Health's animal ethics committee.
Six-week-old, male Sprague Dawley rats were treated with fluoxetine, imipramine, lithium carbonate, and sodium valproate according to accepted protocols, which have been shown to result in clinically relevant levels of drug in rat blood (Dean et al., 1997 . Thus, groups of 20 rats were given diet supplemented with 1.8 g lithium carbonate (Sigma Aldrich, Sydney, Australia)/ kg diet, 12 g sodium valproate (Sigma Aldrich, Sydney, Australia)/ kg diet, or control chow for 4 weeks. In addition, groups of 20 rats were administered 10 mg/kg/d fluoxetine (Eli Lilly West Ryde, Australia), 20 mg/kg/d imipramine (Sigma Aldrich, Sydney, Australia), or 0.9% saline via i.p. injection for either 10 (acute) or 28 (chronic) days. These 2 treatment periods are frequently studied in rats, as they result in differing CNS molecular (Dean et al., 1997) and behavioral (Naudon et al., 2007) effects. At the completion of the treatment period, rats were sacrificed by decapitation, and the brain tissue was removed, rapidly frozen in isopentane on dry ice, and stored at -80 o C until required.
In Situ Radioligand Binding
[ 3 H]AF-DX 384 binding was performed as previously described (Crook et al., 1999) . Thus, 20-µm frozen sections were cut from BA 24 and BA 46 and from rats at ~2 mm rostral to bregma and thaw-mounted on to gelatinized slides. All sections were incubated at room temperature in assay buffer (10 (Crook et al., 1999) , and under such conditions the specific binding of [ 3 H]AF-DX 384 is a good measure of the total number of binding sites in a tissue section (McKinney, 2006) . Sections were then washed twice for 2 minutes in ice-cold assay buffer, rinsed in ice-cold distilled water, and dried in a stream of cool air before being fixed overnight in paraformaldehyde vapor; this gives a level of fixation that stabilizes the tissue section without affecting radioligand binding properties (Liberatore et al., 1999) .
Oxotremorine-M-Stimulated, [
S]GTPγS Binding Assay
[ 35 S]GTPγS binding was essentially performed as described previously , and hence, 20-µm frozen sections were cut from BA 24 and BA 46 and thaw-mounted on to gelatinized slides. Sections (n = 5) from each subject were incubated in assay buffer (20 mM HEPES containing 100 mM NaCl and 5 mM MgCl 2 , pH 7.4 and 0.2 mM guanosine diphosphate) for 30 minutes at room temperature before being rinsed in distilled water and dried in a stream of cool air. Sections were then incubated with 0.05 nM [
35 S]GTPγS (Perkin Elmer, Waltham, MA) in assay buffer with (stimulated-binding; 3 sections/subject) or without (basal binding; 2 sections/subject) 100 μM oxotremorine-M for 60 minutes at room temperature. Slides were then washed twice for 15 minutes in ice-cold assay buffer without GDP, rinsed in dH 2 O, dried in a stream of cool air, and partially fixed overnight in paraformaldehyde vapor. S]GTPγS, the partially fixed frozen sections were apposed to BAS-TR2025 plates (Fujifilm, Tokyo, Japan) for 7 days or BAS-SR2025 plates (Fujifilm, Tokyo, Japan) overnight, respectively. Each plate was also exposed to autoradiographic microscales (Amersham Biosciences, Little Chalfort, UK). The plates were imaged using a BAS5000 high-resolution phosphoimager (Fujifilm, Tokyo, Japan) and analyzed using AIS imaging software (Imaging Research, St. Catharines, ON, Canada 
CHRM2 Protein
To validate the specificity of the CHRM2 antibody, Western blots were initially performed using homogenates from BA 46 and the frontal cortex of muscarinic M2 receptor knockout (CHRM2 -/-) and wild-type (w/t) mice (Gomeza et al., 1999) (gift from Lilly Research Laboratories). In completing these and the experiments comparing CHRM2 protein levels across psychiatric disorders, our experience agrees with the proposition that it is extremely difficult to find CNS reference proteins that, by definition, do not change levels between CNS regions, with disorders of the human CNS, or after drug treatments (Eaton et al., 2013; Rena Li and Shen, 2013 ). Hence, we followed the suggestion that protein load should be controlled for by carefully measuring protein levels in each cortical homogenate and carefully controlling the volume of each sample loaded on each gel, rather than using a single reference as a loading control (Eaton et al., 2013) . Thus, to measure CHRM2 levels, samples of BA 24, BA 46, or mouse frontal cortex were homogenized with 5 strokes of a Teflon-glass homogenizer into 10 mM Tris-HCl containing 1% SDS and 0.1 mM Na 3 VO 4 (pH 7.4) on ice, with the Na 3 VO 4 being added on the day of use. The protein concentration in each homogenate was then measured using the BioRad protein assay with internally produced quality controls in every assay to allow the identification of unacceptable assay to assay variation.
An aliquot of each cortical homogenate containing exactly 30 μg protein was then electrophoresed, in duplicate, on a 7.5% polyacrylamide gel and transferred onto nitrocellulose membranes. Each membrane was then stained with Ponceau S and examined for any variation in overall levels of protein transfer (Klein et al., 1995) . To visualize CHRM2, the nitrocellulose membranes were blocked with 5% nonfat milk powder (NFMP) in Tris buffered saline and 0.1% Tween-20 (TTBS) for 1 hour before being incubated overnight with 1:1000 rabbit anti-CHRM2 antibody in 5% NFMP (AB-5166 Merck Millipore, Kilsyth, Australia) at 4°C, washed thrice for 10 minutes in TTBS, and then incubated with 1:2000 HRP-conjugated, goat anti-rabbit secondary antibody (DAKO, Glostrup, Denmark) in 5% NFMP for 1 hour at room temperature. The membranes were washed thrice in TTBS, incubated for 5 minutes in SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific Pierce, Rockford, IL), and the intensity of the immunogenic bands was measured using the Kodak CF 440 image station. To further limit any variation, the exposure of each gel was standardized to an Internal Control (IC), which was run on each gel. The IC is a homogenate prepared from tissue from a donor who is not part of the study cohort and is first run, under the optimized conditions, in every lane of 2 gels to allow the intensity of immunogenic labelling of the protein of interest to be measured 24 times. These readings must not vary by more than 10% and are used to establish target range for the protein of interest (mean ± 2SD of all repeated measures). The IC was then run on every subsequent gel, along with the unknowns, and chemiluminesence of the IC used to guide exposure time so that the intensity of the IC fell within the established range. The intensity of the immunogenic band representing the protein of interest was then expressed as a ratio of the IC.
Statistics
D'Agostino & Pearson omnibus normality test was used to determine whether data sets followed a Gaussian distribution. Demographic and CNS collection data as well as experimental data from the analyses of human and rat CNS tissue was compared using 1-way ANOVA followed by Tukey's posttest. Chi-square tests were used to determine if the frequency of categorical data (sex and suicide) varied between diagnoses. Data from suicide completers and death by other causes (see below) were compared using 
Results
Demographic and CNS Collection Data
There were no significant differences in age, duration of illness, and PMI or the gender balance between diagnostic cohorts (Table 1; supplementary Table 1 ). There was significant variance in CNS pH, because pH was higher in MDD. There was significant difference in frequency of suicide completion across diagnoses even when rates of suicide were compared in BPD and MDD. Figure 1C ) and therefore an integrated measure across the whole cortex was taken.
Studies Using Human Cortex
Oxotremorine-M stimulated, [
35 S]GTPγS binding showed significant variance with diagnoses in BA 24 (F = 4.14; df = 2,45; P = .02), but not BA 46 (F = 0.71; df = 2,45; P = .50) ( Figure 1D ). The variation in BA 24 was due to lower oxotremorine-M stimulated, [ Figure 1D ).
Western Blotting
To validate the specificity of the anti-CHRM2 antibody, we showed it recognized a 66-kDA immunogenic band in the cortex of wild type but not Chrm2 -/-mice ( Figure 2A ). These data showed the anti-CHRM2 antibody targets an epitope on the mammalian Chrm2. In every sample of human cortex, we visualized the CHRM2 at 65 kDA as predicted from human fibroblasts (Buchli et al., 1999) . The antibody cross reacted with an immunogenic band at 71 kDa of unknown identity in all human cortical samples.
There was significant variation in the CHRM2 protein (F = 3.88; df = 2,44; P = .03) with diagnoses in BA 24 ( Figure 2B) ; the variance in CHRM2 protein approached, but did not reach, significance (F = 1.11, df = 2,44, P = .39; F = 2.92, df = 2,43, P = .07) in BA 46. Post-hoc analyses showed that, compared to controls, the variance in BA 24 was due to lower levels of CHRM2 in BPD (P = .04; Cohen's d = -0.77) and MDD (P = .04; Cohen's d = -0.82). 
Potential Confounding Factors
Our experimental data did not vary with gender (males vs females P = .11 to 0.84) and there were no strong relationships between our experimental data and age (r 2 from 3. Table 1 ). Importantly, there was no strong correlation between CNS pH and our experimental data with all but one regression line not deviating significantly from the horizontal (supplementary Table 2 ). The regression line describing the relationship between CNS pH and [ 35 S]GTPγS binding in BA24 from the controls did deviate significantly from the horizontal but the relationship was too weak to impact on the outcome of comparing experimental data across diagnoses (Cook and Weisberg, 1999) . Finally, there were no strong correlations between levels of [ (Table 1 ) and, as a nonnumeric variable, could not be interrogated with linear regression, its impact was therefore assessed by it being analysed as a primary variable. When these analyses were completed using non-psychiatric subjects and psychiatric nonsuicides, [ (Table 2) . When the same data was analysed without data from the controls [ 
Neuropsychopharmacological Studies
All drug treatments had complex effects on [ 3 H]AF-DX 384 binding in rat CNS which raises the possibility that both mood stabilisers and antidepressant drugs may act, in part, by altering levels of muscarinic receptors in the CNS.
Mood Stabilisers
The most profound effect of drug treatment was an increase in [
3 H]AF-DX 384 binding after treatment with lithium (supplementary Table 3 ). Compared to vehicle, treatment with lithium was associated with higher levels of [ or imipramine (10 mg / kg / day). 1 p < 0.05, 2 p < 0.01, 3 p < 0.001, 4 p < 0.0001 In = inner layer, Out = outer layer disorders is supported our finding of reduced CHRM2 / 4 mediated G-protein signalling in BA 24 from subjects with those disorders as this is the first post-receptor event modulating CHRM2 negative feedback. Hence our data raises the possibility that the proven antidepressant effects of the pan-CHRM antagonist scopolamine (Furey and Drevets, 2006; Drevets and Furey, 2010) , and the potential antidepressant effects of drugs that target the nicotinic receptors (X. Li et al., 2012) , involves the modulation of a hypercholinergic state in the cortex of subjects with mood disorders.
